Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia - PubMed
12 hours ago
- #clinical trial
- #chemotherapy-induced thrombocytopenia
- #romiplostim
- Romiplostim was tested against placebo in a phase 3 trial for chemotherapy-induced thrombocytopenia (CIT).
- The study involved 165 patients with gastrointestinal cancers, primarily colorectal cancer (75%).
- Patients received romiplostim or placebo for three chemotherapy cycles.
- 84% of romiplostim-treated patients had no CIT-induced chemotherapy modifications, compared to 36% in the placebo group.
- Adverse events of grade 3 or higher occurred in 37% of romiplostim patients and 22% of placebo patients.
- Thromboembolic events occurred in 2% of romiplostim patients and none in the placebo group.
- Romiplostim was found efficacious in treating CIT with manageable side effects.